Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

NCT06547203 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: Cetuximab
DRUG: Toripalimab
DRUG: Irinotecan

Sponsor

Sun Yat-sen University